The efficacy and safety of endo-radiofrequency for the treatment of hidradenitis suppurativa.
clinical trial
efficacy
hidradenitis suppurativa
radiofrequency
safety
Journal
Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
ISSN: 1600-0846
Titre abrégé: Skin Res Technol
Pays: England
ID NLM: 9504453
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
05
08
2023
accepted:
17
08
2023
medline:
27
9
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
Hidradenitis suppurativa (HS) is a chronic and recurrent disease of the axilla and groin with inflammatory lesions. There is no definitive medication or intervention to cure the disease. Radiofrequency (RF) is a modality to destroy the lesions by transferring heat into the skin. To date, few studies have been conducted to evaluate the efficacy and safety of RF at HS. This 9-month, prospective, nonrandomized, and single-blinded study is a clinical trial conducted in 10 patients with refractory HS. In all patients, the initial grade of HS was evaluated. The procedure involved treating HS of the axilla with a endo-RF wave device. Post-treatment evaluation included: determination of the severity of the disease by a blinded dermatologist, the degree of patient satisfaction, tolerability in each patient, and complications of the procedure. We also evaluate the recurrence of the disease during a 6-month follow-up. The satisfaction level after the intervention among under-studied cases was excellent and good in six of cases. There was a significant difference in comparing the grading score of patients before and 3 months after receiving RF (P-value: 0.01). Regarding tolerability, eight of the patients could tolerate it. We had no complication after the intervention and four cases had not recurrence during a 6-month follow-up. Endo-RF is an effective and safe modality for treating HS however to prevent the recurrence, periodic therapy sessions are needed.
Sections du résumé
BACKGROUND
BACKGROUND
Hidradenitis suppurativa (HS) is a chronic and recurrent disease of the axilla and groin with inflammatory lesions. There is no definitive medication or intervention to cure the disease. Radiofrequency (RF) is a modality to destroy the lesions by transferring heat into the skin. To date, few studies have been conducted to evaluate the efficacy and safety of RF at HS.
METHODS
METHODS
This 9-month, prospective, nonrandomized, and single-blinded study is a clinical trial conducted in 10 patients with refractory HS. In all patients, the initial grade of HS was evaluated. The procedure involved treating HS of the axilla with a endo-RF wave device. Post-treatment evaluation included: determination of the severity of the disease by a blinded dermatologist, the degree of patient satisfaction, tolerability in each patient, and complications of the procedure. We also evaluate the recurrence of the disease during a 6-month follow-up.
RESULTS
RESULTS
The satisfaction level after the intervention among under-studied cases was excellent and good in six of cases. There was a significant difference in comparing the grading score of patients before and 3 months after receiving RF (P-value: 0.01). Regarding tolerability, eight of the patients could tolerate it. We had no complication after the intervention and four cases had not recurrence during a 6-month follow-up.
CONCLUSION
CONCLUSIONS
Endo-RF is an effective and safe modality for treating HS however to prevent the recurrence, periodic therapy sessions are needed.
Identifiants
pubmed: 37753687
doi: 10.1111/srt.13450
pmc: PMC10462799
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13450Informations de copyright
© 2023 The Authors. Skin Research and Technology published by John Wiley & Sons Ltd.
Références
N Engl J Med. 2012 Jan 12;366(2):158-64
pubmed: 22236226
Dermatol Surg. 2008 Jan;34(1):114-7
pubmed: 18053033
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44
pubmed: 25640693
J Am Acad Dermatol. 2007 Apr;56(4):621-3
pubmed: 17097366
Am J Clin Dermatol. 2020 Apr;21(2):237-243
pubmed: 31845121
J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S70-7
pubmed: 26470621
Dermatol Surg. 2008 Feb;34(2):228-31
pubmed: 18093196
F1000Prime Rep. 2014 Dec 01;6:112
pubmed: 25580266
J Dermatolog Treat. 2021 Aug;32(5):530-537
pubmed: 31609667
Lasers Surg Med. 2009 Feb;41(2):87-95
pubmed: 19226570
Br J Dermatol. 2008 Dec;159(6):1309-14
pubmed: 19036028
Clin Exp Dermatol. 2022 Feb;47(2):335-342
pubmed: 34431555
Expert Rev Clin Pharmacol. 2018 Sep;11(9):879-887
pubmed: 30136871
Plast Reconstr Surg. 2016 Sep;138(3 Suppl):219S-229S
pubmed: 27556765
Dermatol Surg. 2014 Dec;40 Suppl 12:S168-73
pubmed: 25417570